Ferring Drug Patent Portfolio

Ferring owns 3 orange book drugs protected by 12 US patents Given below is the list of Ferring's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10695398 Method of treating prostate cancer with GnRH antagonist 27 Apr, 2032
Active
US11766468 Method of treating prostate cancer with GnRH antagonist 27 Apr, 2032
Active
US11826397 Method of treating prostate cancer with GnRH antagonist 27 Apr, 2032
Active
US9415085 Method of treating prostate cancer with GnRH antagonist 27 Apr, 2032
Active
US10729739 Methods of treating prostate cancer with GnRH antagonist 10 Feb, 2029
Active
US10973870 Methods of treating prostate cancer with GnRH antagonist 10 Feb, 2029
Active
US9579359 Method of treating prostate cancer with GnRH antagonist 10 Feb, 2029
Active
US7022340 Pharmaceutical composition as solid dosage form and method for manufacturing thereof 30 Apr, 2023 Expired
US5925730 GnRH antagonists 18 May, 2021 Expired
US7300664 Vaginally administrable progesterone-containing tablets and method for preparing same 17 Nov, 2019 Expired
US7320800 Vaginally administrable progesterone-containing tablets and method for preparing same 17 Nov, 2019 Expired
US7393543 Vaginally administratable progesterone-containing tablets and method for preparing same 17 Nov, 2019 Expired


Given below is the list of recent legal activities going on the following drug patents of Ferring.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 06 Feb, 2024 US9415085
Payment of Maintenance Fee, 4th Year, Large Entity 23 Jan, 2024 US10729739
Payment of Maintenance Fee, 4th Year, Large Entity 19 Dec, 2023 US10695398
Email Notification 29 Nov, 2023 US11826397
Recordation of Patent Grant Mailed 28 Nov, 2023 US11826397
Patent eGrant Notification 28 Nov, 2023 US11826397
Patent Issue Date Used in PTA Calculation 28 Nov, 2023 US11826397
Mail Patent eGrant Notification 28 Nov, 2023 US11826397
Recordation of Patent eGrant 28 Nov, 2023 US11826397
Email Notification 09 Nov, 2023 US11826397
Issue Notification Mailed 08 Nov, 2023 US11826397
Application Is Considered Ready for Issue 19 Oct, 2023 US11826397
Dispatch to FDC 19 Oct, 2023 US11826397
Issue Fee Payment Received 18 Oct, 2023 US11826397
Issue Fee Payment Verified 18 Oct, 2023 US11826397


Ferring Drug Patents' Oppositions Filed in EPO

Ferring drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 23, 2015, by Generics (Uk) Ltd (Trading As Mylan). This opposition was filed on patent number EP09711390A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP13168404A Dec, 2015 Generics [UK] Ltd (trading as Mylan) Revoked
EP13168404A Dec, 2015 Fresenius Kabi Deutschland GmbH Revoked
EP12165896A Sep, 2015 Fresenius Kabi Deutschland GmbH Revoked
EP12165896A Sep, 2015 Generics [UK] Limited (trading as Mylan) Revoked
EP09711390A Jan, 2015 Generics (UK) Ltd (trading as Mylan) Revoked


Ferring's Family Patents

Ferring drugs have patent protection in a total of 25 countries. It's US patent count contributes only to 16.8% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Ferring Drug List

Given below is the complete list of Ferring's drugs and the patents protecting them.


1. Desmopressin Acetate

Desmopressin Acetate is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7022340 Pharmaceutical composition as solid dosage form and method for manufacturing thereof 30 Apr, 2023
(1 year, 5 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Desmopressin Acetate's drug page


2. Endometrin

Endometrin is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7300664 Vaginally administrable progesterone-containing tablets and method for preparing same 17 Nov, 2019
(4 years ago)
Expired
US7320800 Vaginally administrable progesterone-containing tablets and method for preparing same 17 Nov, 2019
(4 years ago)
Expired
US7393543 Vaginally administratable progesterone-containing tablets and method for preparing same 17 Nov, 2019
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Endometrin's drug page


3. Firmagon

Firmagon is protected by 8 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10695398 Method of treating prostate cancer with GnRH antagonist 27 Apr, 2032
(7 years from now)
Active
US11766468 Method of treating prostate cancer with GnRH antagonist 27 Apr, 2032
(7 years from now)
Active
US11826397 Method of treating prostate cancer with GnRH antagonist 27 Apr, 2032
(7 years from now)
Active
US9415085 Method of treating prostate cancer with GnRH antagonist 27 Apr, 2032
(7 years from now)
Active
US10729739 Methods of treating prostate cancer with GnRH antagonist 10 Feb, 2029
(4 years from now)
Active
US10973870 Methods of treating prostate cancer with GnRH antagonist 10 Feb, 2029
(4 years from now)
Active
US9579359 Method of treating prostate cancer with GnRH antagonist 10 Feb, 2029
(4 years from now)
Active
US5925730 GnRH antagonists 18 May, 2021
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Firmagon's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List